Status:

COMPLETED

First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension

Lead Sponsor:

University of Calgary

Collaborating Sponsors:

Actelion

Conditions:

Hypertension, Pulmonary

Eligibility:

All Genders

18-85 years

Brief Summary

The purpose of this study is to evaluate the strategy of initiating double oral combination therapy with bosentan and sildenafil at the time of diagnosis of pulmonary arterial hypertension (PAH) in a ...

Detailed Description

Current treatment paradigms for PAH suggest adopting goals of therapy with relatively objective parameters such as 6 minute walk distance to determine when to add a second oral agent (1). This often e...

Eligibility Criteria

Inclusion

  • Patients with symptomatic Functional Class III PAH in the following categories: Idiopathic (IPAH), Familial (FPAH), Associated with connective tissue disease, Associated with drugs or toxins
  • PAH diagnosed by right heart catheterization, defined as: mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg, PVR \> 3 mmHg/l/min (Wood units) or \> 240 dyn sec cm-5, pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
  • Baseline 6 MWT distance \> 150 and \< 450 m

Exclusion

  • Treatment with ERAs other than bosentan;
  • Treatment with PDE5 inhibitors other than sildenafil;
  • Treatment with any prostanoid;
  • PAH associated with thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders and splenectomy; valvular disease with valvular lesions to be excluded by echocardiogram within 2 years prior to randomization
  • Restrictive lung disease: total lung capacity (TLC) \< 60% of normal predicted value;
  • Obstructive lung disease: forced expiratory volume/forced vital capacity (FEV1/FVC) \< 50%

Key Trial Info

Start Date :

December 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2015

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT01247116

Start Date

December 1 2009

End Date

December 1 2015

Last Update

June 12 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Calgary, Peter Lougheed Hospital

Calgary, Alberta, Canada, T1Y 6J4

First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension | DecenTrialz